{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epigenetic+Disorder&page=2",
    "query": {
      "condition": "Epigenetic Disorder",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epigenetic+Disorder&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T02:46:41.483Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06189027",
      "title": "Epigenetics and MDMA-Assisted Psychotherapy for PTSD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "PTSD"
      ],
      "interventions": [
        {
          "name": "MDMA",
          "type": "DRUG"
        },
        {
          "name": "Psychotherapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2018-11-20",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-07-24T02:46:41.483Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06189027"
    },
    {
      "nct_id": "NCT02395627",
      "title": "Reversing Therapy Resistance With Epigenetic-Immune Modification",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2015-05-04",
      "completion_date": "2019-06-08",
      "has_results": true,
      "last_update_posted_date": "2020-07-07",
      "last_synced_at": "2026-07-24T02:46:41.483Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02395627"
    },
    {
      "nct_id": "NCT03638687",
      "title": "Neuroimaging Epigenetics of Prospective Postpartum Depression Biomarkers",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Post Partum Depression",
        "Bipolar Disorder"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 80,
      "start_date": "2014-05",
      "completion_date": "2020-08",
      "has_results": false,
      "last_update_posted_date": "2020-09-22",
      "last_synced_at": "2026-07-24T02:46:41.483Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03638687"
    },
    {
      "nct_id": "NCT06717243",
      "title": "Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Small Cell Lung Cancer",
        "Large Cell Neuroendocrine (NE) Tumors",
        "Treatment Failure",
        "Biomarkers / Blood",
        "Biomarkers",
        "Immunotherapy"
      ],
      "interventions": [
        {
          "name": "Carboplatin/Cisplatin -Etoposide - Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oncology Center of Biochemical Education And Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 111,
      "start_date": "2025-02-20",
      "completion_date": "2028-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-03-19",
      "last_synced_at": "2026-07-24T02:46:41.483Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06717243"
    },
    {
      "nct_id": "NCT07103018",
      "title": "A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer",
        "Metastatic Castration-Resistant Prostate Cancer Patients",
        "Metastatic Castration-resistant Prostate Cancer, mCRPC",
        "mCRPC",
        "mCRPC (Metastatic Castration-resistant Prostate Cancer)"
      ],
      "interventions": [
        {
          "name": "KTX-2001",
          "type": "DRUG"
        },
        {
          "name": "KTX-2001 + Darolutamide (NUBEQA®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "K36 Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 144,
      "start_date": "2025-11-21",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-07-24T02:46:41.483Z",
      "location_count": 13,
      "location_summary": "San Francisco, California • Miami, Florida • Port Saint Lucie, Florida + 8 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07103018"
    },
    {
      "nct_id": "NCT02204020",
      "title": "Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)",
        "Myelodysplastic Syndrome (MDS)"
      ],
      "interventions": [
        {
          "name": "5-azacytidine (5-aza) maintenance therapy after transplant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2015-04",
      "completion_date": "2016-05-04",
      "has_results": false,
      "last_update_posted_date": "2018-03-30",
      "last_synced_at": "2026-07-24T02:46:41.483Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02204020"
    },
    {
      "nct_id": "NCT07224854",
      "title": "Epigenetic Signature for CRC Early Detection",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Colorectal Cancer (Diagnosis)",
        "Non-cancer Controls",
        "DNA Methylation",
        "Cell Free DNA",
        "Early Detection of Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2024-06-21",
      "completion_date": "2028-06-18",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-07-24T02:46:41.483Z",
      "location_count": 1,
      "location_summary": "Monrovia, California",
      "locations": [
        {
          "city": "Monrovia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07224854"
    },
    {
      "nct_id": "NCT06694454",
      "title": "Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer (NSCLC)",
        "Carcinoma, Non-Small Cell Lung",
        "Non-Small Cell Lung Carcinoma",
        "Non Small Cell Lung Cancer",
        "Non Small Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "azacytidine",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "durvalumab",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 60,
      "start_date": "2026-07-28",
      "completion_date": "2034-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-07-24T02:46:41.483Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06694454"
    },
    {
      "nct_id": "NCT03526666",
      "title": "Ascorbic Acid Levels in MDS, AML, and CMML Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Myelodysplastic Syndromes",
        "Acute Myeloid Leukemia",
        "Chronic Myelomonocytic Leukemia",
        "MDS",
        "AML",
        "CMML"
      ],
      "interventions": [
        {
          "name": "Peripheral blood collection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Van Andel Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2017-11-01",
      "completion_date": "2018-10-31",
      "has_results": false,
      "last_update_posted_date": "2019-10-03",
      "last_synced_at": "2026-07-24T02:46:41.483Z",
      "location_count": 2,
      "location_summary": "Grand Rapids, Michigan • Wyoming, Michigan",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Wyoming",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03526666"
    },
    {
      "nct_id": "NCT07060001",
      "title": "Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)",
        "Acute Myeloid Leukaemia (AML)"
      ],
      "interventions": [
        {
          "name": "5hmC Biomarker",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Decitabine 20 mg/m²/day for 5 days",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (AZA)",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine (Ara-C)",
          "type": "DRUG"
        },
        {
          "name": "Anthracycline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "DRUG"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 112,
      "start_date": "2026-04",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-07-24T02:46:41.483Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07060001"
    }
  ]
}